Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 4/2015

01-04-2015 | Original Article

C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms

Authors: Juan F. Combariza, Milton Lombana, Luis E. Pino, Marcos Arango

Published in: Supportive Care in Cancer | Issue 4/2015

Login to get access

Abstract

Objective

The objective of this study is to assess the prognostic usefulness of the Multinational Association of Supportive Care in Cancer (MASCC) risk score in association with the value of C-reactive protein (CRP) to identify high-risk patients with febrile neutropenia and hematologic neoplasms.

Methods

A retrospective cohort study in which the MASCC score and the CRP values were used to assess the mortality risk at 30 days among patients with febrile neutropenia and hematologic malignancies was performed.

Results

Two hundred thiry-seven patients with febrile neutropenia were analyzed; the mortality rate within 30 days was 9 %. High-risk patients according to the MASCC score were significantly more likely to experience adverse outcomes, such as being transferred to the intensive care unit (RR 3.55; CI 95 % 2.73–6.62, p < 0.001) and death (RR 2.21; CI 95 % 1.74–2.79, p < 0.001). Multivariate analysis showed a strong association between the high-risk group identified by the MASCC score (HR 3.0; CI 95 % 1.12–13.54, p = 0.032) and the mean levels of CRP (HR 17; CI 95 % 2.21–136.48, p = 0.007) and survival. The survival rate within 30 days was 100 % for the patients with a low-risk MASCC score and a mean CRP less than 15 mg/dL. This rate was only 64 % for high-risk patients with a mean CRP greater than 15 mg/dL.

Conclusion

The MASCC risk score combined with the mean CRP value successfully identifies patients with febrile neutropenia and hematological malignancies and a high risk of death.
Appendix
Available only for authorised users
Literature
1.
Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39(Suppl 1):S32–S37CrossRefPubMed
2.
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340CrossRefPubMed
3.
Rosenberg PS, Alter BP, Bolyard AA, Bonilla MA, Boxer LA, Cham B et al (2006) The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood 107:4628–4635CrossRefPubMedCentralPubMed
4.
Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39(Suppl 1):S25–S31CrossRefPubMed
5.
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
6.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431CrossRefPubMed
7.
Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS et al (2011) Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 19:1151–1158CrossRefPubMed
8.
Hui EP, Leung LK, Poon TC, Mo F, Chan VT, Ma AT et al (2011) Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer 19:1625–1635CrossRefPubMed
9.
Ahn S, Lee YS, Lim KS, Lee JL (2013) Adding procalcitonin to the MASCC risk index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 21:2303–2308CrossRefPubMed
10.
Elligsen M, Walker SA, Walker SE, LePiane F, Lathia N, De’Angelis C et al (2012) Comparison of mortality between nosocomial and community-acquired febrile neutropenia patients treated initially with cefazolin plus tobramycin: retrospective chart review. Eur J Clin Microbiol Infect Dis 31:1141–1150CrossRefPubMed
11.
Paesmans M, Klastersky J, Maertens J, Georgala A, Muanza F, Aoun M et al (2011) Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter? Support Care Cancer 19:1001–1008CrossRefPubMed
12.
Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179CrossRefPubMed
13.
Baskaran ND, Gan GG, Adeeba K (2008) Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients. Ann Hematol 87:563–569CrossRefPubMed
14.
Haeusler GM, Carlesse F, Phillips RS (2013) An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer. Pediatr Infect Dis J 32:e390–e396CrossRefPubMed
15.
Lin SG, Hou TY, Huang DH, He SY, Lin YD, Zhang LY et al (2012) Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia—a systemic review and meta-analysis. Pediatr Infect Dis J 31(10):e182–e188PubMed
16.
Phillips RS, Wade R, Lehrnbecher T, Stewart LA, Sutton AJ (2012) Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med 10:6CrossRefPubMedCentralPubMed
17.
Miedema KG, de Bont ES, Elferink RF, van Vliet MJ, Nijhuis CS, Kamps WA et al (2011) The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. Support Care Cancer 19:1593–1600CrossRefPubMedCentralPubMed
18.
Schuttrumpf S, Binder L, Hagemann T, Berkovic D, Trumper L, Binder C (2006) Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. Clin Infect Dis 43:468–473CrossRefPubMed
19.
Aznar-Oroval E, Sanchez-Yepes M, Lorente-Alegre P (2010) Valor diagnostico de la procalcitonina, la interleucina 8, la interleucina 6 y la proteína C reactiva en la detección de bacteriemia y fungemia en pacientes con cáncer. Enferm Infecc Microbiol Clin 28:273–277CrossRefPubMed
20.
Ortega M, Rovira M, Almela M (2004) Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. Bone Marrow Transplant 33:741–744CrossRefPubMed
21.
Kitanovski L, Jazbec J, Hojker S, Derganc M (2014) Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein. Support Care Cancer 22:269–277CrossRefPubMed
22.
Massaro K, Costa S, Leone C (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137CrossRefPubMedCentralPubMed
Metadata
Title
C-reactive protein and the MASCC risk index identify high-risk patients with febrile neutropenia and hematologic neoplasms
Authors
Juan F. Combariza
Milton Lombana
Luis E. Pino
Marcos Arango
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 4/2015
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2454-2

Other articles of this Issue 4/2015

Supportive Care in Cancer 4/2015 Go to the issue

Letter to the editor

The role of the OncPal deprescribing guideline in end-of-life care

Review Article

Incorporating measures of sleep quality into cancer studies

Original Article

Pilot evaluation of Scrambler therapy for the treatment of chemotherapy-induced peripheral neuropathy

Original Article

Cytokine gene variations associated with trait and state anxiety in oncology patients and their family caregivers

Original Article

A mindfulness-based program for improving quality of life among hematopoietic stem cell transplantation survivors: feasibility and preliminary findings

Original Article

Readmission rates due to venous thromboembolism in cancer patients after abdominopelvic surgery, a retrospective chart review
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits